Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer

Molecular and Clinical Oncology
Katsuhiro MasagoNobuyuki Katakami

Abstract

Malignant pleural effusion (MPE) is a common complication of lung cancer with devastating consequences. Since vascular endothelial growth factor (VEGF) has been implicated in MPE, we hypothesized that bevacizumab, an anti-VEGF antibody, may be effective against MPE in patients with non-small-cell lung cancer (NSCLC). We analysed the records of 21 patients treated for NSCLC-associated MPE between February, 2010 and August, 2013 who consequently underwent bevacizumab combination chemotherapy at the Institute of Biomedical Research and Innovation Hospital. The results were retrospectively analysed using case records and radiographic imaging records. Three patients exhibited complete response of the pleural effusion to bevacizumab treatment, 8 patients achieved a partial response (PR) and 6 patients showed no response. When efficacy was assessed by the response of the measurable primary or metastatic lesions to the treatment, 5 patients achieved a PR, 13 patients had stable disease and 3 patients exhibited progressive disease. The response rate (RR) of the pleural effusion to the antibody treatment was 71.4% and the overall RR of measurable lesions was 23.8%. The median time-to-response for pleural effusion was 132 days. In conclus...Continue Reading

References

Apr 1, 1974·Cancer·C B AndersonT B Ferguson
Feb 1, 1981·Current Problems in Cancer·A Memon, Z A Zawadzki
Sep 24, 1999·Chest·D ChengR W Light
Sep 29, 1999·Cancer Immunology, Immunotherapy : CII·H YanagawaS Sone
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H JohnsonFairooz Kabbinavar
Aug 19, 2005·The New England Journal of Medicine·Oskar PichelmayerMarkus Raderer
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Sep 1, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Peter GoldstrawUNKNOWN Participating Institutions
Jan 23, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·I-Lin HsuWu-Wei Lai
May 14, 2009·Current Opinion in Pulmonary Medicine·Ali I Musani
Oct 13, 2009·Respirology : Official Journal of the Asian Pacific Society of Respirology·Sabrina C C RibeiroLisete R Teixeira
Oct 5, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Erin M Bertino, Gregory A Otterson
Nov 28, 2012·Cancer Chemotherapy and Pharmacology·Kazuhiro KitamuraAkihiko Gemma
Sep 3, 2013·Clinics in Chest Medicine·Justin M Thomas, Ali I Musani

❮ Previous
Next ❯

Citations

Sep 25, 2017·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Jiyoul YangHye Sook Han
Feb 10, 2019·The Clinical Respiratory Journal·Claire TissotMarios E Froudarakis
Jul 29, 2018·The European Respiratory Journal·Anna C BibbyNick A Maskell
Dec 6, 2018·Reviews on Recent Clinical Trials·Fausto Meriggi
Dec 19, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·D Marquez-Medina, S Popat
Mar 9, 2017·Expert Review of Respiratory Medicine·José M PorcelY C Gary Lee
Jul 31, 2018·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Anna C BibbyGiuseppe Cardillo
Dec 14, 2017·Expert Review of Respiratory Medicine·Ralph Llewel SabangOleg Epelbaum
Mar 25, 2019·Oncoimmunology·Pranav MurthyMichael T Lotze
Dec 5, 2018·Biosensors & Bioelectronics·Xuanying LiZhenzhong Guo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.